Nature Communications

Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trial

2026-04-21

Full text

DOI https://doi.org/10.1038/s41467-026-72245-7